在非小细胞肺癌中进行新辅助EGFR-TKI治疗
Christopher Grant1, Misako Nagasaka2
1Department of Medicine, University of California Irvine Medical Center, Orange CA, USA.
Cancer treatment reviews
|April 18, 2024
概括
早期非小细胞肺癌 (NSCLC) 的新辅助治疗正在发展,试验正在探索EGFR-TKI和免疫疗法组合. 本综述涵盖已完成和正在进行的研究,突出显示NSCLC治疗的未来方向.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 癌症治疗方法 癌症治疗方法
背景情况:
- 早期非小细胞肺癌 (NSCLC) 阶段I-III通常经历手术,免疫疗法和化疗.
- 许多临床试验已经排除了EGFR和ALK等特定遗传变异的患者.
- 新辅助疗法正在成为可切除NSCLC的关键治疗方式.
研究的目的:
- 审查已完成的关于NSCLC新辅助治疗的临床试验.
- 讨论正在进行的试验,评估新辅助性EGFR-TKI单疗法,化疗和免疫疗法组合.
- 分析新辅助NSCLC治疗中的潜在益处,挑战和未来方向.
主要方法:
- 在新辅助性NSCLC治疗中完成的临床试验的文献综述.
- 对正在进行的临床试验的分析,重点关注EGFR-TKI,化疗和免疫疗法组合.
- 讨论新兴趋势和新辅助NSCLC治疗的未来研究途径.
主要成果:
- 几项已完成的试验已经研究了NSCLC的新辅助方法.
- 目前正在进行的试验正在积极评估EGFR-TKI单疗法,化疗和免疫疗法组合.
- 该领域正在迅速发展,具有改善患者治疗结果的巨大潜力.
结论:
- 新辅助疗法,特别是针对性药物和免疫疗法,对早期NSCLC具有前景.
- 需要进一步的研究来优化治疗策略和克服挑战.
- 未来的方向包括完善组合疗法,并解决患有特定遗传改变的患者群体.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160
